Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts

Area of Science:

• Cardiology
• Clinical Pharmacology

Background:

• Ventricular arrhythmias frequently accompany structural heart disease.
• A subset of patients with ventricular arrhythmias have structurally normal hearts; these are often inherited, affect younger individuals, and can lead to sudden cardiac death (SCD).
• Advances in understanding pathophysiology have improved targeted drug therapies over the last two decades.

Purpose of the Study:

• To review current drug therapies for inherited arrhythmia syndromes.
• To review current drug therapies for acquired arrhythmias.
• To provide expert opinion on the optimal use of pharmacotherapy in managing these conditions.

Main Methods:

• Literature review of drug therapy for specific inherited arrhythmia syndromes (Brugada, early repolarization, long QT, short QT, catecholaminergic polymorphic ventricular tachycardia).
• Literature review of drug therapy for acquired arrhythmias (idiopathic ventricular fibrillation, short-coupled torsade de pointes, outflow tract ventricular tachycardia, idiopathic left, papillary muscle, and annular ventricular tachycardias).
• Synthesis of expert opinion on diagnosis, drug selection, and dosing.

Main Results:

• Pharmacological management is crucial for inherited arrhythmia syndromes, with proper diagnosis and drug selection vital for SCD prevention, often avoiding the need for implantable cardioverter-defibrillators.
• Pharmacotherapy can offer symptomatic relief and reduce the need for invasive treatments in selected patients with acquired arrhythmias.
• Current therapies highlight the importance of precise diagnosis and tailored treatment approaches.

Conclusions:

• Accurate clinical and genetic diagnosis is paramount in inherited arrhythmia syndromes for effective pharmacotherapy and SCD prevention.
• Pharmacotherapy plays a significant role in managing both inherited and acquired arrhythmias, improving patient outcomes.
• Further research is necessary to develop novel antiarrhythmic drugs with improved efficacy and reduced side effects.